Gillian Murphy

Q: What Schools Are Affiliated With Gillian Murphy

Gillian Murphy is affiliated with the following schools: University of East Anglia, Tokyo University of Agriculture and Technology, University of Cambridge

Gillian Murphy's AcademicInfluence.com Rankings

Gillian Murphy

Biology

#9172

World Rank

#12342

Historical Rank

Molecular Biology

#1228

World Rank

#1254

Historical Rank

Biochemistry

#1376

World Rank

#1500

Historical Rank

biology Degrees

Download Badge

Biology

Gillian Murphy's Degrees

PhD Biochemistry University of California, Berkeley
Bachelors Chemistry Stanford University

Why Is Gillian Murphy Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Gillian Murphy's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Structure and function of matrix metalloproteinases and TIMPs. (2006) (2935)
Metalloproteinase inhibitors: biological actions and therapeutic opportunities (2002) (1116)
Sequence of human tissue inhibitor of metalloproteinases and its identity to erythroid-potentiating activity (1985) (700)
A novel function for tissue inhibitor of metalloproteinases-3 (TIMP3): inhibition of angiogenesis by blockage of VEGF binding to VEGF receptor-2 (2003) (657)
Tumor necrosis factor-alpha-converting enzyme (ADAM17) mediates the cleavage and shedding of fractalkine (CX3CL1). (2001) (639)
The TIMP2 Membrane Type 1 Metalloproteinase “Receptor” Regulates the Concentration and Efficient Activation of Progelatinase A (1998) (627)
TNF‐α converting enzyme (TACE) is inhibited by TIMP‐3 (1998) (583)
Membrane-type matrix metalloproteinases 1 and 2 exhibit broad-spectrum proteolytic capacities comparable to many matrix metalloproteinases. (1997) (473)
Mechanisms for pro matrix metalloproteinase activation (1999) (450)
Stromelysin is an activator of procollagenase. A study with natural and recombinant enzymes. (1987) (449)
Matrix metalloproteinase degradation of elastin, type IV collagen and proteoglycan. A quantitative comparison of the activities of 95 kDa and 72 kDa gelatinases, stromelysins-1 and -2 and punctuated metalloproteinase (PUMP). (1991) (447)
The in vitro activity of ADAM‐10 is inhibited by TIMP‐1 and TIMP‐3 (2000) (421)
Shedding of Syndecan-1 and -4 Ectodomains Is Regulated by Multiple Signaling Pathways and Mediated by a Timp-3–Sensitive Metalloproteinase (2000) (418)
Degradation of cartilage aggrecan by collagenase‐3 (MMP‐13) (1996) (393)
Tissue inhibitor of metalloproteinase‐1 messenger RNA expression is enhanced relative to interstitial collagenase messenger RNA in experimental liver injury and fibrosis (1996) (337)
The N-terminal domain of tissue inhibitor of metalloproteinases retains metalloproteinase inhibitory activity. (1991) (328)
ADAM 12-S cleaves IGFBP-3 and IGFBP-5 and is inhibited by TIMP-3. (2000) (327)
Relating matrix metalloproteinase structure to function: why the "hemopexin" domain? (1997) (315)
Correction for Substrate Selectivity of Epidermal Growth Factor-Receptor Ligand Sheddases and their Regulation by Phorbol Esters and Calcium Influx (2006) (305)
TNF-alpha converting enzyme (TACE) is inhibited by TIMP-3. (1998) (297)
Inhibition of invasion and induction of apoptotic cell death of cancer cell lines by overexpression of TIMP-3 (1999) (296)
The role of the C-terminal domain in collagenase and stromelysin specificity. (1992) (290)
Reappraising metalloproteinases in rheumatoid arthritis and osteoarthritis: destruction or repair? (2008) (287)
The interglobular domain of cartilage aggrecan is cleaved by PUMP, gelatinases, and cathepsin B. (1992) (280)
The C-terminal domain of 72 kDa gelatinase A is not required for catalysis, but is essential for membrane activation and modulates interactions with tissue inhibitors of metalloproteinases. (1992) (271)
Endothelial tubulogenesis within fibrin gels specifically requires the activity of membrane-type-matrix metalloproteinases (MT-MMPs). (2002) (257)
ERK-mediated phosphorylation of Thr735 in TNFα-converting enzyme and its potential role in TACE protein trafficking (2005) (254)
Identification and characterization of human MT5-MMP, a new membrane-bound activator of progelatinase a overexpressed in brain tumors. (1999) (251)
Membrane type I-matrix metalloproteinase (MT1-MMP) is internalised by two different pathways and is recycled to the cell surface (2003) (250)
Intermolecular Autolytic Cleavage Can Contribute to the Activation of Progelatinase A by Cell Membranes (*) (1995) (247)
The Role of Plasmhogen Activators in the Regulation of Connective Tissue Metalloproteinases a (1992) (245)
Identification and structural and functional characterization of human enamelysin (MMP-20). (1997) (238)
The activity of the tissue inhibitors of metalloproteinases is regulated by C-terminal domain interactions: a kinetic analysis of the inhibition of gelatinase A. (1993) (236)
ADAMTS1 cleaves aggrecan at multiple sites and is differentially inhibited by metalloproteinase inhibitors. (2002) (235)
Membrane Type 4 Matrix Metalloproteinase (MMP17) Has Tumor Necrosis Factor-α Convertase Activity but Does Not Activate Pro-MMP2* (2000) (224)
Assessment of the role of the fibronectin-like domain of gelatinase A by analysis of a deletion mutant. (1994) (221)
Human hepatic lipocytes synthesize tissue inhibitor of metalloproteinases-1. Implications for regulation of matrix degradation in liver. (1992) (214)
Tissue inhibitor of metalloproteinases-2 inhibits the activation of 72 kDa progelatinase by fibroblast membranes. (1991) (206)
Pump-1 cDNA codes for a protein with characteristics similar to those of classical collagenase family members. (1989) (197)
Activation of progelatinase B (proMMP-9) by active collagenase-3 (MMP-13). (1997) (195)
Interaction of metargidin (ADAM-15) with alphavbeta3 and alpha5beta1 integrins on different haemopoietic cells. (1999) (195)
Meltrin gamma(ADAM-9) mediates cellular adhesion through alpha(6)beta(1 )integrin, leading to a marked induction of fibroblast cell motility. (2000) (188)
Accelerated apoptosis in the Timp-3-deficient mammary gland. (2001) (187)
The tissue metalloproteinase family and the inhibitor TIMP: a study using cDNAs and recombinant proteins. (1990) (186)
Structural insights into triple-helical collagen cleavage by matrix metalloproteinase 1 (2012) (184)
The matrix metalloproteinases and their natural inhibitors: prospects for treating degenerative tissue diseases. (1992) (183)
Membrane-type-2 matrix metalloproteinase can initiate the processing of progelatinase A and is regulated by the tissue inhibitors of metalloproteinases. (1997) (180)
Matrix Metalloproteinases MMP2 and MMP9 Are Produced in Early Stages of Kidney Morphogenesis but Only MMP9 Is Required for Renal Organogenesis In Vitro (1997) (176)
Tumor Necrosis Factor-α-converting Enzyme (TACE/ADAM-17) Mediates the Ectodomain Cleavage of Intercellular Adhesion Molecule-1 (ICAM-1)* (2006) (171)
High preoperative plasma tissue inhibitor of metalloproteinase-1 levels are associated with short survival of patients with colorectal cancer. (2000) (167)
Cleavage of cartilage proteoglycan between G1 and G2 domains by stromelysins. (1991) (160)
Src-mediated Tyrosine Phosphorylation of Caveolin-1 Induces Its Association with Membrane Type 1 Matrix Metalloproteinase* (2004) (160)
Gingival fibroblasts degrade type I collagen films when stimulated with tumor necrosis factor and interleukin 1: evidence that breakdown is mediated by metalloproteinases. (1989) (156)
Evidence for a Critical Role of the Tumor Necrosis Factor α Convertase (TACE) in Ectodomain Shedding of the p75 Neurotrophin Receptor (p75NTR)* (2004) (155)
Analysis of the role of the COOH-terminal domain in the activation, proteolytic activity, and tissue inhibitor of metalloproteinase interactions of gelatinase B. (1994) (155)
Quantitation of TIMP-1 in plasma of healthy blood donors and patients with advanced cancer (1999) (155)
Physiological mechanisms for metalloproteinase activation. (1992) (152)
Thiol isomerases negatively regulate the cellular shedding activity of ADAM17. (2010) (152)
The matrix metalloproteinases and their inhibitors. (1995) (151)
Fibroblast and neutrophil collagenases cleave at two sites in the cartilage aggrecan interglobular domain. (1993) (151)
The enzymatic activity of ADAM8 and ADAM9 is not regulated by TIMPs (2002) (147)
The 28-kDa N-terminal domain of mouse stromelysin-3 has the general properties of a weak metalloproteinase. (1993) (146)
Total levels of tissue inhibitor of metalloproteinases 1 in plasma yield high diagnostic sensitivity and specificity in patients with colon cancer. (2002) (144)
Up-regulation of Vascular Endothelial Growth Factor-A by Active Membrane-type 1 Matrix Metalloproteinase through Activation of Src-Tyrosine Kinases* (2004) (141)
Inhibition of angiogenesis by tissue inhibitor of metalloproteinase-3. (1997) (141)
The helping hand of collagenase-3 (MMP-13): 2.7 A crystal structure of its C-terminal haemopexin-like domain. (1996) (139)
Matrix metalloproteinases and metastatic cancer. (1998) (131)
Degradation of entactin by matrix metalloproteinases. Susceptibility to matrilysin and identification of cleavage sites. (1993) (131)
Matrilysin is much more efficient than other matrix metalloproteinases in the proteolytic inactivation of alpha 1-antitrypsin. (1994) (129)
Activation of pro-(matrix metalloproteinase-2) (pro-MMP-2) by thrombin is membrane-type-MMP-dependent in human umbilical vein endothelial cells and generates a distinct 63 kDa active species. (2001) (129)
Individual Timp Deficiencies Differentially Impact Pro-MMP-2 Activation* (2006) (125)
Extracellular regulation of metalloproteinases. (2015) (124)
A Heterogeneous In Vitro Three Dimensional Model of Tumour-Stroma Interactions Regulating Sprouting Angiogenesis (2012) (122)
Fibroblast growth factor receptor 1 is principally responsible for fibroblast growth factor 2-induced catabolic activities in human articular chondrocytes (2011) (121)
Increased matrix metalloproteinase-13 production with aging by human articular chondrocytes in response to catabolic stimuli. (2005) (119)
Tissue inhibitor of metalloproteinase-I and interstitial collagenase expression in autoimmune chronic active hepatitis and activated human hepatic lipocytes. (1995) (119)
Neutrophil collagenase (MMP-8) cleaves at the aggrecanase site E373-A374 in the interglobular domain of cartilage aggrecan. (1994) (118)
Detection and localization of mRNAs encoding matrix metalloproteinases and their tissue inhibitor in human breast pathology. (1993) (118)
Cross-domain inhibition of TACE ectodomain (2011) (116)
The matrix metalloprotease matrilysin (PUMP) is expressed in developing human mononuclear phagocytes. (1992) (114)
Matrix metalloproteinase-1 associates with intracellular organelles and confers resistance to lamin A/C degradation during apoptosis. (2005) (112)
Cytokine stimulated vascular cell adhesion molecule-1 (VCAM-1) ectodomain release is regulated by TIMP-3. (2005) (112)
Cellular activation of proMMP‐13 by MT1‐MMP depends on the C‐terminal domain of MMP‐13 (2002) (109)
Solution structure of the active domain of tissue inhibitor of metalloproteinases-2. A new member of the OB fold protein family. (1994) (106)
Overexpression of matrix metalloproteinase-10 and matrix metalloproteinase-3 in human diabetic corneas: a possible mechanism of basement membrane and integrin alterations. (2001) (105)
Shedding of Endogenous Interleukin-6 Receptor (IL-6R) Is Governed by A Disintegrin and Metalloproteinase (ADAM) Proteases while a Full-length IL-6R Isoform Localizes to Circulating Microvesicles* (2015) (103)
Recognition and catabolism of synthetic heterotrimeric collagen peptides by matrix metalloproteinases. (2000) (102)
Structure-function relationships in the tissue inhibitors of metalloproteinases. (1994) (101)
The soluble form of a disintegrin and metalloprotease 33 promotes angiogenesis: implications for airway remodeling in asthma. (2008) (100)
Human and rat malignant-tumor-associated mRNAs encode stromelysin-like metalloproteinases. (1989) (98)
ADAM28 is overexpressed in human non‐small cell lung carcinomas and correlates with cell proliferation and lymph node metastasis (2006) (98)
Catalytic activities of membrane‐type 6 matrix metalloproteinase (MMP25) (2001) (95)
Human myeloma cells shed the interleukin‐6 receptor: inhibition by tissue inhibitor of metalloproteinase‐3 and a hydroxamate‐based metalloproteinase inhibitor (1998) (95)
Cell surface-mediated activation of progelatinase A: demonstration of the involvement of the C-terminal domain of progelatinase A in cell surface binding and activation of progelatinase A by primary fibroblasts. (1994) (94)
Immunoassays for the detection of human collagenase, stromelysin, tissue inhibitor of metalloproteinases (TIMP) and enzyme-inhibitor complexes. (1990) (92)
Membrane-Type 1 Matrix Metalloproteinase Stimulates Cell Migration through Epidermal Growth Factor Receptor Transactivation (2007) (91)
Effects of collagenase-cleavage of type I collagen on alpha2beta1 integrin-mediated cell adhesion. (1998) (91)
Metalloproteinases and tissue damage. (1991) (88)
Serum TIMP-1, TIMP-2, and MMP-1 in patients with systemic sclerosis, primary Raynaud's phenomenon, and in normal controls. (2001) (86)
The Specificity of TIMP-2 for Matrix Metalloproteinases Can Be Modified by Single Amino Acid Mutations* (1999) (86)
Role and regulation of metalloproteinases in connective tissue turnover. (1990) (86)
Phosphinic pseudo-tripeptides as potent inhibitors of matrix metalloproteinases: a structure-activity study. (1999) (85)
Biochemical characterization of matrilysin. Activation conforms to the stepwise mechanisms proposed for other matrix metalloproteinases. (1992) (84)
CD30 Shedding from Karpas 299 Lymphoma Cells Is Mediated by TNF-α-Converting Enzyme1 (2000) (84)
Site-directed mutations that alter the inhibitory activity of the tissue inhibitor of metalloproteinases-1: importance of the N-terminal region between cysteine 3 and cysteine 13. (1992) (83)
Tumor Tissue Concentrations of the Proteinase Inhibitors Tissue Inhibitor of Metalloproteinases-1 (TIMP-1) and Plasminogen Activator Inhibitor Type 1 (PAI-1) Are Complementary in Determining Prognosis in Primary Breast Cancer * (2003) (82)
Comprehensive profiling and localisation of the matrix metalloproteinases in urothelial carcinoma (2006) (82)
Sites of nidogen cleavage by proteases involved in tissue homeostasis and remodelling. (1993) (82)
Metalloproteases Cleave the Urokinase-Type Plasminogen Activator Receptor in the D1-D2 Linker Region and Expose Epitopes not Present in the intact Soluble Receptor (2002) (82)
Different domain interactions are involved in the binding of tissue inhibitors of metalloproteinases to stromelysin-1 and gelatinase A. (1994) (80)
Membrane-type 1-Matrix Metalloproteinase Regulates Intracellular Adhesion Molecule-1 (ICAM-1)-mediated Monocyte Transmigration* (2007) (78)
Anti-Tumour Effects of a Specific Anti-ADAM17 Antibody in an Ovarian Cancer Model In Vivo (2012) (77)
Metalloproteinase and tissue inhibitor of metalloproteinase expression in the murine STR/ort model of osteoarthritis. (2002) (76)
Activation of human neutrophil procollagenase by stromelysin 2. (1996) (75)
Membrane-Type Matrix Metalloproteinases and Cell Surface-Associated Activation Cascades for Matrix Metalloproteinases (1998) (71)
Membrane-type 4 matrix metalloproteinase promotes breast cancer growth and metastases. (2006) (70)
Identification of the Extracellular Matrix (ECM) Binding Motifs of Tissue Inhibitor of Metalloproteinases (TIMP)-3 and Effective Transfer to TIMP-1* (2007) (70)
Immunolocalization of Matrix Metalloproteinases in Partial-Thickness Defects in Pig Articular Cartilage: A Preliminary Report (2001) (69)
MT1-MMP regulates VEGF-A expression through a complex with VEGFR-2 and Src (2010) (68)
Unveiling the Surface Epitopes That Render Tissue Inhibitor of Metalloproteinase-1 Inactive against Membrane Type 1-Matrix Metalloproteinase* (2003) (67)
ADAM10 mediates trastuzumab resistance and is correlated with survival in HER2 positive breast cancer (2014) (67)
Purification of recombinant human prostromelysin. Studies on heat activation to give high-Mr and low-Mr active forms, and a comparison of recombinant with natural stromelysin activities. (1991) (66)
Dissecting the Role of Matrix Metalloproteinases (MMP) and Integrin αvβ3 in Angiogenesis In vitro: Absence of Hemopexin C Domain Bioactivity, but Membrane-Type 1-MMP and αvβ3 Are Critical (2005) (66)
TIMP-3 Inhibition of ADAMTS-4 (Aggrecanase-1) Is Modulated by Interactions between Aggrecan and the C-terminal Domain of ADAMTS-4* (2007) (65)
New N-arylsulfonyl-N-alkoxyaminoacetohydroxamic acids as selective inhibitors of gelatinase A (MMP-2). (2004) (65)
Dissociation of tissue inhibitor of metalloproteinases (TIMP) from enzyme complexes yields fully active inhibitor. (1989) (65)
Amber force field implementation, molecular modelling study, synthesis and MMP-1/MMP-2 inhibition profile of (R)- and (S)-N-hydroxy-2-(N-isopropoxybiphenyl-4-ylsulfonamido)-3-methylbutanamides. (2006) (65)
Mutation of the active site glutamic acid of human gelatinase A: effects on latency, catalysis, and the binding of tissue inhibitor of metalloproteinases-1. (1994) (64)
Role of TIMPs (tissue inhibitors of metalloproteinases) in pericellular proteolysis: the specificity is in the detail. (2003) (60)
Full-length and N-TIMP-3 display equal inhibitory activities toward TNF-alpha convertase. (2001) (59)
The intrinsic protein flexibility of endogenous protease inhibitor TIMP-1 controls its binding interface and affects its function. (2010) (59)
Perivascular cells regulate endothelial membrane type-1 matrix metalloproteinase activity. (2001) (59)
Development of recombinant adenoviruses that drive high level expression of the human metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 and -2 genes: characterization of their infection into rabbit smooth muscle cells and human MCF-7 adenocarcinoma cells. (1996) (58)
Sequence motifs of tissue inhibitor of metalloproteinases 2 (TIMP-2) determining progelatinase A (proMMP-2) binding and activation by membrane-type metalloproteinase 1 (MT1-MMP). (2003) (57)
Total Conversion of Tissue Inhibitor of Metalloproteinase (TIMP) for Specific Metalloproteinase Targeting (2005) (57)
Proteolytic inactivation of human α1 antitrypsin by human stromelysin (1991) (56)
Decoy receptors block TRAIL sensitivity at a supracellular level: the role of stromal cells in controlling tumour TRAIL sensitivity (2016) (56)
Threonine 98, the Pivotal Residue of Tissue Inhibitor of Metalloproteinases (TIMP)-1 in Metalloproteinase Recognition* (2004) (54)
Kinetic analysis of the mechanism of interaction of full-length TIMP-2 and gelatinase A: evidence for the existence of a low-affinity intermediate. (1998) (54)
CD30 shedding from Karpas 299 lymphoma cells is mediated by TNF-alpha-converting enzyme. (2000) (54)
The gene structure of tissue inhibitor of metalloproteinases (TIMP)-3 and its inhibitory activities define the distinct TIMP gene family. (1996) (53)
Functional Significance of MMP-9 in Tumor Necrosis Factor-Induced Proliferation and Branching Morphogenesis of Mammary Epithelial Cells. (2000) (52)
Proteolysis of human native and oxidised α1-proteinase inhibitor by matrulysin and stromelysin (1994) (51)
Targeting ADAM-17 with an inhibitory monoclonal antibody has antitumour effects in triple-negative breast cancer cells (2015) (51)
Stromelysin (MMP‐3) Synthesis Is Up‐Regulated in Estrogen‐Deficient Mouse Osteoblasts In Vivo and In Vitro (1999) (51)
Interaction of metargidin (ADAM-15) with αvβ3 and α5β1 integrins on different haemopoietic cells (1999) (50)
Different susceptibilities of fibulin-1 and fibulin-2 to cleavage by matrix metalloproteinases and other tissue proteases. (1996) (50)
Expression of the type IV collagenase system during mouse kidney development and tubule segmentation. (2001) (49)
Senescence‐associated release of transmembrane proteins involves proteolytic processing by ADAM17 and microvesicle shedding (2014) (48)
Engineering N-terminal domain of tissue inhibitor of metalloproteinase (TIMP)-3 to be a better inhibitor against tumour necrosis factor-alpha-converting enzyme. (2002) (45)
The isolated N-terminal domains of TIMP-1 and TIMP-3 are insufficient for ADAM10 inhibition. (2008) (43)
Inhibition of Shedding of Low‐Density Lipoprotein Receptor–Related Protein 1 Reverses Cartilage Matrix Degradation in Osteoarthritis (2017) (43)
Chemically and conformationally authentic active domain of human tissue inhibitor of metalloproteinases-2 refolded from bacterial inclusion bodies. (1996) (42)
Expression and modulation of matrix metalloproteinase-2 and tissue inhibitors of metalloproteinases in human embryonic CNS stem cells. (1999) (42)
Targeting the Sheddase Activity of ADAM17 by an Anti-ADAM17 Antibody D1(A12) Inhibits Head and Neck Squamous Cell Carcinoma Cell Proliferation and Motility via Blockage of Bradykinin Induced HERs Transactivation (2014) (41)
Metalloproteinase domain structure, cellular invasion and metastasis. (1994) (41)
Altered MicroRNA Expression after Infection with Human Cytomegalovirus Leads to TIMP3 Downregulation and Increased Shedding of Metalloprotease Substrates, Including MICA (2014) (41)
Meltrin γ (ADAM-9) mediates cellular adhesion through α6β1 integrin, leading to a marked induction of fibroblast cell motility (2000) (40)
Gelatinase A possesses a β‐secretase‐like activity in cleaving the amyloid protein precursor of Alzheimer's disease (1995) (40)
Cell-mediated degradation of type IV collagen and gelatin films is dependent on the activation of matrix metalloproteinases. (1992) (38)
Inhibition of MT1-MMP activity using functional antibody fragments selected against its hemopexin domain. (2012) (38)
Dissecting the role of matrix metalloproteinases (MMP) and integrin alpha(v)beta3 in angiogenesis in vitro: absence of hemopexin C domain bioactivity, but membrane-Type 1-MMP and alpha(v)beta3 are critical. (2005) (38)
Selective inhibition of ADAM12 catalytic activity through engineering of tissue inhibitor of metalloproteinase 2 (TIMP-2). (2010) (38)
Functional significance of MMP-9 in tumor necrosis factor-induced proliferation and branching morphogenesis of mammary epithelial cells. (2000) (38)
Role of the Netrin-like Domain of Procollagen C-Proteinase Enhancer-1 in the Control of Metalloproteinase Activity* (2010) (38)
Overexpression of the oncostatin M receptor in cervical squamous cell carcinoma cells is associated with a pro‐angiogenic phenotype and increased cell motility and invasiveness (2011) (37)
Antibody-based exosite inhibitors of ADAMTS-5 (aggrecanase-2) (2015) (37)
MT1-MMP regulates urothelial cell invasion via transcriptional regulation of Dickkopf-3 (2008) (36)
Two novel determinants of etoposide resistance in small cell lung cancer. (2011) (36)
Mapping and characterization of the functional epitopes of tissue inhibitor of metalloproteinases (TIMP)‐3 using TIMP‐1 as the scaffold: A new frontier in TIMP engineering (2002) (35)
Golgi reassembly stacking protein 55 interacts with membrane‐type (MT) 1‐matrix metalloprotease (MMP) and furin and plays a role in the activation of the MT1‐MMP zymogen (2010) (34)
Development of a specific affinity-matured exosite inhibitor to MT1-MMP that efficiently inhibits tumor cell invasion in vitro and metastasis in vivo (2016) (34)
Bcl-2 and β1-integrin predict survival in a tissue microarray of small cell lung cancer (2010) (33)
The C‐terminal domains of TACE weaken the inhibitory action of N‐TIMP‐3 (2002) (33)
Measurement of the noncomplexed free fraction of tissue inhibitor of metalloproteinases 1 in plasma by immunoassay. (2002) (32)
Indoxyl sulfate, a uremic toxin in chronic kidney disease, suppresses both bone formation and bone resorption (2017) (32)
N-i-Propoxy-N-biphenylsulfonylaminobutylhydroxamic acids as potent and selective inhibitors of MMP-2 and MT1-MMP. (2005) (32)
Direct Melanoma Cell Contact Induces Stromal Cell Autocrine Prostaglandin E2-EP4 Receptor Signaling That Drives Tumor Growth, Angiogenesis, and Metastasis* (2015) (32)
Pentosan polysulfate increases affinity between ADAMTS-5 and TIMP-3 through formation of an electrostatically driven trimolecular complex (2012) (31)
LPS activates ADAM9 dependent shedding of ACE from endothelial cells. (2012) (31)
Delineating the Molecular Basis of the Inactivity of Tissue Inhibitor of Metalloproteinase-2 against Tumor Necrosis Factor-α-converting Enzyme* (2004) (31)
Tissue Inhibitor of Metalloproteinases-3 Peptides Inhibit Angiogenesis and Choroidal Neovascularization in Mice (2013) (30)
Tailoring TIMPs for Selective Metalloproteinase Inhibition (2008) (30)
Development of a 'mouse and human cross-reactive' affinity-matured exosite inhibitory human antibody specific to TACE (ADAM17) for cancer immunotherapy. (2014) (30)
Membrane Type 1 Matrix Metalloproteinase (MT1-MMP) Ubiquitination at Lys581 Increases Cellular Invasion through Type I Collagen* (2012) (30)
Lactoferricin mediates anabolic and anti‐catabolic effects in the intervertebral disc (2012) (30)
Establishment and Characterization of 7 New Monoclonal Antibodies to Tissue Inhibitor of Metalloproteinases-1 (2005) (28)
Absence of p300 induces cellular phenotypic changes characteristic of epithelial to mesenchyme transition (2006) (28)
BA321, a novel carborane analog that binds to androgen and estrogen receptors, acts as a new selective androgen receptor modulator of bone in male mice. (2016) (27)
The activity of a designer tissue inhibitor of metalloproteinases (TIMP)-1 against native membrane type 1 matrix metalloproteinase (MT1-MMP) in a cell-based environment. (2010) (27)
Modulation of integrin α4β1 by ADAM28 promotes lymphocyte adhesion and transendothelial migration (2011) (26)
Adam 33 and its association with airway remodeling and hyperresponsiveness in asthma (2004) (26)
The Recognition Sites of the Integrins α1β1 and α2β1 within Collagen IV Are Protected against Gelatinase A Attack in the Native Protein* (1996) (26)
Tailoring tissue inhibitor of metalloproteinases-3 to overcome the weakening effects of the cysteine-rich domains of tumour necrosis factor-alpha converting enzyme. (2003) (26)
Cellular cholesterol regulates MT1 MMP dependent activation of MMP 2 via MEK‐1 in HT1080 fibrosarcoma cells (2004) (25)
Tissue Banking of Diagnostic Lung Cancer Biopsies for Extraction of High Quality RNA (2010) (25)
Granulocyte‐macrophage colony stimulating factor induces endothelial capillary formation through induction of membrane‐type 1 matrix metalloproteinase expression in vitro (2008) (24)
Membrane type 1-matrix metalloproteinase induces endothelial cell morphogenic differentiation by a caspase-dependent mechanism. (2005) (23)
Use of a multiple-enzyme/multiple-reagent assay system to quantify activity levels in samples containing mixtures of matrix metalloproteinases. (2004) (23)
The regulation of connective tissue metalloproteinases by natural inhibitors. (1991) (22)
A new development of matrix metalloproteinase inhibitors: twin hydroxamic acids as potent inhibitors of MMPs. (2005) (22)
ADAM 33: just another asthma gene or a breakthrough in understanding the origins of bronchial hyperresponsiveness? (2003) (22)
The MET/Vascular Endothelial Growth Factor Receptor (VEGFR)-targeted Tyrosine Kinase Inhibitor Also Attenuates FMS-dependent Osteoclast Differentiation and Bone Destruction Induced by Prostate Cancer* (2016) (21)
Anti‐tumor effects of a ‘human & mouse cross‐reactive’ anti‐ADAM17 antibody in a pancreatic cancer model in vivo (2017) (20)
Absence of p300 induces cellular phenotypic changes characteristic of epithelial to mesenchyme transition (2006) (19)
Proteolysis of human native and oxidised alpha 1-proteinase inhibitor by matrilysin and stromelysin. (1994) (18)
Effects of collagenase-cleavage of type I collagen on α 2 β 1 integrin-mediated cell adhesion (1998) (17)
Folding and stability of the active N-terminal domain of tissue inhibitor of metalloproteinases-1 and -2. (1994) (17)
The role of exon 5 in fibroblast collagenase (MMP-1) substrate specificity and inhibitor selectivity. (2001) (16)
TIMP-3 facilitates binding of target metalloproteinases to the endocytic receptor LRP-1 and promotes scavenging of MMP-1 (2019) (16)
Characterization of the AB Loop Region of TIMP-2 (2006) (14)
Gelatinase A possesses a beta-secretase-like activity in cleaving the amyloid protein precursor of Alzheimer's disease. (1995) (13)
MT1-MMP hemopexin domain exchange with MT4-MMP blocks enzyme maturation and trafficking to the plasma membrane in MCF7 cells. (2006) (13)
Structural analysis of tissue inhibitor of metalloproteinases-1 (TIMP-1) by tryptic peptide mapping. (1993) (13)
Investigation of the role of Endo180/urokinase-type plasminogen activator receptor-associated protein as a collagenase 3 (matrix metalloproteinase 13) receptor (2002) (13)
The Aminopeptidase CD13 Induces Homotypic Aggregation in Neutrophils and Impairs Collagen Invasion (2016) (12)
ADAM9 is present at endothelial cell - cell junctions and regulates monocyte – endothelial transmigration (2017) (12)
ADAM17-dependent proteolysis of L-selectin promotes early clonal expansion of cytotoxic T cells (2019) (12)
Proteolytic inactivation of human alpha 1 antitrypsin by human stromelysin. (1991) (11)
Mechanism of Heparin Acceleration of Tissue Inhibitor of Metalloproteases-1 (TIMP-1) Degradation by the Human Neutrophil Elastase (2011) (10)
One-step Sandwich Enzyme Immunoassays for Human Matrix Metalloproteinase 13(Collagenase-3)using Monoclonal Antibodies (1998) (10)
Dissociation of tissue inhibitor of metalloproteinases (TIMP) from enzyme complexes yields fully active inhibitor. (1989) (10)
Tissue Inhibitor of Metalloproteinase–3 (TIMP-3) induces FAS dependent apoptosis in human vascular smooth muscle cells (2018) (10)
The recognition sites of the integrins alpha1beta1 and alpha2beta1 within collagen IV are protected against gelatinase A attack in the native protein. (1996) (9)
Two Secreted Proteoglycans, Activators of Urothelial Cell–Cell Adhesion, Negatively Contribute to Bladder Cancer Initiation and Progression (2020) (8)
Isolation and characterisation of a chicken gelatinase (type IV collagenase). (1991) (8)
Raloxifene reduces the risk of local alveolar bone destruction in a mouse model of periodontitis combined with systemic postmenopausal osteoporosis. (2018) (7)
Development of a monoclonal anti-ADAMTS-5 antibody that specifically blocks the interaction with LRP1 (2017) (7)
Assessment of gelatinase expression and activity in articular cartilage. (2007) (7)
Crystallization and preliminary X-ray analysis of a truncated tissue metalloproteinase inhibitor delta 128-194 TIMP-2. (1993) (7)
Erratum: The gene structure of tissue inhibitor of metalloproteinases (TIMP)-3 and its inhibitory activities define the distinct TIMP gene family (Journal of Biological Chemistry (1995) 270 (14313-14318)) (1996) (7)
Methods for studying activation of matrix metalloproteinases. (2010) (6)
Identification and possible functions of ADAM33 as an asthma susceptibility gene (2004) (6)
Methods for studying activation of matrix metalloproteinases. (2001) (6)
COLLAGENASE-3 (MMP-13) C-TERMINAL HEMOPEXIN-LIKE DOMAIN (1996) (5)
Abrogation of prostaglandin E-EP4 signaling in osteoblasts prevents the bone destruction induced by human prostate cancer metastases. (2016) (5)
N-terminal domain of tissue inhibitor of metalloproteinase ( TIMP )-3 to be a better inhibitor against tumour necrosis factor-α-converting enzyme (4)
Speci ¢ c collagenolysis by gelatinase A , MMP-2 , is determined by the hemopexin domain and not the ¢ bronectin-like domain (2001) (4)
Evidence for the importance of weakly bound water for matrix metalloproteinase activity. (1995) (4)
1 Role of the NTR domain of procollagen C-proteinase enhancer-1 in the control of metalloproteinase activity * (2010) (4)
Metalloproteinases in Cartilage Matrix Breakdown: The Roles in Rheumatoid Arthritis and Osteoarthritis (2013) (4)
ADAM 17-dependent proteolysis of L-selectin promotes early clonal expansion of cytotoxic T cells (2019) (4)
Investigation of the role of Endo180/urokinase-type plasminogen activator receptor-associated protein as a collagenase 3 (matrix metalloproteinase 13) receptor. (2002) (4)
Molecular biology (pre-clinical) (2012) (3)
The N-terminal domain of tissue inhibitor of metalloproteinases retains metalloproteinase inhibitor activity [Erratum to document cited in CA115(9):88133x] (1991) (3)
Advances in Brief Identification and Characterization of Human MT 5-MMP , a New Membrane-bound Activator of Progelatinase A Overexpressed in Brain Tumors 1 (2000) (3)
MT 1-MMP hemopexin domain exchange with MT 4-MMP blocks enzyme maturation and trafficking to the plasma membrane in MCF 7 cells (2006) (2)
Biochemistry meets biology: key findings for bone calcification and a lifetime philosophy of collaboration (2011) (2)
Inhibition of LRP1 shedding reverses cartilage degradation in osteoarthritis (2018) (2)
Role of collagenase-3 (MMP-13) in cartilage resportion as observed during the development of the secondary ossification center in the tibia of young rates. I. synthesis and secretion of procollagenase-3 at sites of cartilage (2003) (1)
Membrane type matrix metalloproteinases: regulators of focal proteolysis (1999) (1)
Tissue Inhibitor of Metalloproteinase-1 is Expressed by Hepatic Lipocytes and Upregulated in Cirrhosis and CCl4-Induced Liver (1994) (1)
ArticleTwo Secreted Proteoglycans (2020) (0)
Involvement of collagenase-3 (MMP-13) in the collagen breakdown required for the excavation of the cartilaginous epiphysis of the developing rat long bone (2002) (0)
Carbachol induces ERK1/2 activation and stimulates cell proliferation via a metalloproteinase- and Tgfα-dependent pathway (2003) (0)
527 ADAM17 as a Therapeutic Target for the Treatment of Breast Cancer: Preclinical Studies with an Inhibitory Monoclonal Antibody (2012) (0)
Study of the distribution of metalloproteinases and their tissue inhibitor in human mammary gland lesions. (1990) (0)
129 – Gelatinase A (2004) (0)
The role of matrix metalloproteinases (MMPs) in the arthritides (1998) (0)
The trap hypothesis: α2M and protease inhibition (2006) (0)
MMP-2, MMP-9 and MMP-14 in Breast cancer : clinicalpathological correlation. (2010) (0)
Modulation of Matrix Metalloproteinases Controls Fibroblast Scarring Activity and Minimises Ocular Scarring following Experimental Surgery (2003) (0)
Abstract 328: ADAM17-induced activation of HER receptors mediate resistance to trastuzumab in a subset of moderate HER2-expressing breast cancer cells (2019) (0)
Down-regulation of MT1-MMP leads to inhibition of invasion and increased expression of anti-migratory gene in urothelial carcinoma cell line (2007) (0)
Calcium pentosan polysulfate increases affinity between aggrecanases (ADAMTS-4 and-5) and TIMP-3 by a conformational change (2010) (0)
Enzyme -Converting a Cells Is Mediated by TNF-CD30 Shedding from Karpas 299 Lymphoma (2000) (0)
The trap hypothesis: alpha2M and protease inhibition (2006) (0)
S93 Is Bcl-2 important in small cell lung cancer? (2010) (0)
86P The Role of Adam17 in Her2 Moderately Expressing Breast Cancer (2012) (0)
Design, Synthesis and Inhibitory Properties of Potent Sulfonyl Diaryl Based MMPs and TACE inhibitors (2005) (0)
MMPs and ADAMs as targets for therapies in arthritis (2007) (0)
432 ADAM17 is a psoriasis-relevant check-point controlling Th17-programming by inflammatory dermal dendritic cells (2016) (0)
Crystal structure of MMP-1(E200A) in complex with a triple-helical collagen peptide (2012) (0)
Chapter 37 Tailoring TIMPs for Selective Metalloproteinase Inhibition (0)
Design, synthesis and biological properties of new potent and selective sulfonamide-based inhibitors of gelatinase A (2003) (0)
Mechanism of Induction of Choroidal Neovascularization in Sorsby Fundus Dystrophy (2003) (0)
INTERLEUKIN-1 ALPHA STIMULATES ADAM17-MEDIATED ECTODOMAIN SHEDDING OF LRP1 AND REDUCES ENDOCYTOSIS OF AGGRECANASES IN ARTICULAR CARTILAGE (2015) (0)
Abstract 2724: Activity of the specific anti-ADAM17 inhibitory IgG antibody (Ab), D1(A12) in an ovarian cancer modelin vivo (2012) (0)
MMP inhibition modulates protease production and matrix contraction by myofibroblasts in mechanically loaded collagen gels. (2004) (0)
Extracellular regulation of Kazuhiro Yama (2015) (0)
Matrix Metallopeptidase-2/Gelatinase A (2013) (0)
Synthetic MMP Inhibitors: Slow-Binding Behaviour of Enantioselective N-O-Sulfonamido Based Inhibitors Directed to Specific Matrixins (2007) (0)
Matrix metalloproteinase expression and function in urothelial carcinoma (2005) (0)
Molecular mechanisms of acetylcholine-induced ERK1/2 activation in HT29 cells and isolated human colonic crypts (2002) (0)
Syddansk Universitet Development of a specific affinity-matured exosite inhibitor to MT1-MMP that efficiently inhibits tumor cell invasion in vitro and metastasis in vivo Botkjaer, (2016) (0)
Design of Selective Collagenase 3 (MMP-13) Inhibitors as Potential Therapeutic Agents in Rheumatoid Arthritis (2008) (0)
ADAM17-dependent proteolysis of L-selectin promotes early clonal expansion of cytotoxic T cells (2019) (0)
Carbachol induced calcium signals induce metalloproteinase dependent shedding of TGFα and downstream activation of mitogenic epidermal growth factor receptor signals in HT29 colonic epithelial cells (2004) (0)
ADAM17, Tumor Necrosis Factor α-Convertase (2013) (0)
Inhibition of LRP1 shedding reverses cartilage matrix degradation in osteoarthritis (2017) (0)
Abstract 557: Pharmacological Inhibition of ADAM17 by a Human-Cross Reactive Antibody and Selective Inhibitor JG26 Prevents Vascular Fibrosis Induced by Angiotensin II in vivo and in vitro (2016) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Gillian Murphy?

Gillian Murphy is affiliated with the following schools:

Gillian Murphy's Academic­Influence.com Rankings

Gillian Murphy's Degrees

Why Is Gillian Murphy Influential?

Gillian Murphy's Published Works

Published Works

What Schools Are Affiliated With Gillian Murphy?

Gillian Murphy's AcademicInfluence.com Rankings